Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Medtronic
Harvard Business School
Moodys
QuintilesIMS
Queensland Health
Daiichi Sankyo
Argus Health
Boehringer Ingelheim
Cantor Fitzgerald

Generated: January 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,955,488

« Back to Dashboard

Summary for Patent: 5,955,488
Title: Freeze-dried compositions
Abstract:The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
Inventor(s): Winterborn; Ian Keith (Ware, GB)
Assignee: Glaxo Wellcome Inc. (Mississauga, CA)
Application Number:09/066,762
Patent Claims: 1. A method of treating a condition mediated through the action of 5HT at 5HT.sub.3 receptors in man, which comprises swallowing a rapidly disintegrated orally administered freeze-dried dosage form of a composition comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients.

2. The method of claim 1, wherein the ondansetron is in the form of its free base.

3. The method of claim 1, wherein ondansetron, expressed as free base, comprises 0.1 to 10% w/w of the composition.

4. The method of claim 2, wherein the amount of ondansetron in the composition, comprises 0.1 to 10% w/w of the composition.

5. The method of claim 1, wherein the amount of ondansetron in the composition, expressed as free base, is in the range of 0.1 to 100 mg.

6. The method of claim 2, wherein the amount of ondansetron in the composition, expressed as free base, is in the range of 0.1 to 100 mg.

7. The method of claim 3, wherein the amount of ondansetron in the composition, expressed as free base, is in the range of 0.1 to 100 mg.

8. The method of claim 1, wherein the composition comprises ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavoring aid, aspartame, and mannitol.

9. The method of claim 3, wherein the composition comprises ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavoring aid, aspartame, and mannitol.

10. The method of claim 4, wherein the composition comprises ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavoring aid, aspartame, and mannitol.

11. The method of claim 5, wherein the composition comprises ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavoring aid, aspartame, and mannitol.

12. The method of claim 6, wherein the composition comprises ondansetron in the form of its free base, gelatin, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, strawberry flavoring aid, aspartame, and mannitol.

13. The method of claim 3 for the treatment of emesis.

14. The method of claim 2 for the treatment of emesis.

15. The method of claim 4 for the treatment of emesis.

16. The method of claim 5 for the treatment of emesis.

17. The method of claim 6 for the treatment of emesis.

18. The method of claim 8 for the treatment of emesis.

19. The method of claim 9 for the treatment of emesis.

20. A method of treating a condition mediated through the action of 5HT at 5HT.sub.3 receptors in a mammal which comprises swallowing a rapidly disintegrated orally administered freeze-dried dosage form of a composition comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Teva
Julphar
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim
Argus Health
Covington
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot